Showing results (11-20 of 578) with videos related to
Sort By:
Pageof 58
Thrombosis and Haemostasis|December 29, 2000
Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysisM Marchetti, A Pistorio, G BarosiBritish Journal of Cancer|September 22, 1998
Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemiaG Barosi, M Marchetti, N L LiberatoHaematologica|August 24, 1999
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacementM Marchetti, N L Liberato, N Ruperto, et al.The American Journal of Medicine|August 11, 2001
Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysisM Marchetti, A Pistorio, M Barone, et al.American Journal of Hematology|June 1, 1989
Relative iron deficiency in hereditary spherocytosisA Zanella, G Barosi, A Berzuini, et al.British Journal of Haematology|July 27, 2001
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasiaG Barosi, A Grossi, B Comotti, et al.European Journal of Haematology|June 26, 2001
Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survivalF Cervantes, G Barosi, J C Hernández-Boluda, et al.Blood|November 24, 2001
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasiaG Barosi, G Viarengo, A Pecci, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 6, 2006
Information models for data sharingS QuagliniBlood|November 1, 1983
Biologic and clinical significance of red cell ferritinM Cazzola, L Dezza, G Bergamaschi, et al.Pageof 58